Foresee Pharmaceuticals Co., Ltd.

Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)

Role: lead

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD

Role: lead

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Role: lead

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

Role: lead

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer

Role: lead

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Role: lead

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Role: collaborator

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

Role: lead

The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.

Role: lead

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Role: lead

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Role: lead

Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045

Role: lead

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Role: lead

Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Role: lead

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Role: lead

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Role: lead